Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT04727424

Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Led by Cardresearch · Updated on 2024-05-08

7819

Participants Needed

12

Research Sites

179 weeks

Total Duration

On this page

Sponsors

C

Cardresearch

Lead Sponsor

C

Cytel Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a potential anti-inflammatory role of Fluvoxamine, Fluoxetine, Budesonide and Spirulin Platensis in SARS-CoV-2 infections and observational studies have suggested a reduced complications in patients with COVID-19 disease.

CONDITIONS

Official Title

Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 18 years or older able to provide informed consent
  • Acute flu-like symptoms lasting less than 7 days
  • Presence of at least one risk factor: age over 50, diabetes requiring medication, hypertension treated with medication, known cardiovascular disease, symptomatic lung disease or asthma, obesity (BMI > 30), transplant, chronic kidney disease stage IV or dialysis, temperature over 38ºC at screening, certain symptoms (cough, dyspnea, chest pain, myalgias), immunosuppression or corticosteroid use (up to 10 mg prednisone equivalent), history of cancer within 5 years or current cancer treatment
  • Positive SARS-CoV-2 antigen or diagnostic test within 7 days of symptom onset
  • Willingness to use study treatments and follow study procedures
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Negative SARS-CoV-2 test with acute flu-like symptoms (unless later positive within 7 days of symptoms)
  • Acute respiratory illness expected to require hospitalization
  • Respiratory symptoms caused by other conditions
  • Dyspnea due to other respiratory diseases or infections
  • Hospitalization required or oxygen saturation ≤ 93%
  • Abnormal vital signs or serious organ injury requiring intensive treatment (specific to 7-day treatment arms)
  • Use of high-dose corticosteroids (>40 mg prednisone equivalent daily) or ongoing immunosuppressive therapy
  • History of pulmonary hypertension or pulmonary fibrosis
  • Recent complete COVID-19 vaccination within 6 months or booster dose prior to randomization
  • Use of serotonin reuptake inhibitors (except sertraline for some arms)
  • Participation in other clinical trials with interacting medications within 3 months
  • Phenylketonuria (for 14-day treatment arm)
  • Use of monoamine oxidase inhibitors
  • Severe psychiatric disorders
  • Pregnant or breastfeeding
  • History of severe cardiac arrhythmias or certain heart diseases
  • Planned surgery or hospitalization during treatment or shortly after
  • Uncontrolled alcohol use
  • Recent or uncontrolled seizures
  • Severe liver disease or cirrhosis
  • Severe neurological or mental illnesses
  • Inability to consent or follow study procedures
  • Hypersensitivity or intolerance to study medications
  • Use of medications interacting with study drugs
  • Inability to use study medications and formulations provided

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 12 locations

1

CARDRESEARCH - Cardiologia Assistencial e de Pesquisa

Belo Horizonte, Minas Gerais, Brazil, 30150240

Actively Recruiting

2

City of Betim

Betim, Minas Gerais, Brazil, 32550770

Actively Recruiting

3

City of Brumadinho

Brumadinho, Minas Gerais, Brazil, 35.460-000

Not Yet Recruiting

4

Hospital e Maternidade Santa Rita

Contagem, Minas Gerais, Brazil, 32215000

Actively Recruiting

5

City of Governador Valadares

Governador Valadares, Minas Gerais, Brazil, 35010-000

Actively Recruiting

6

City of Ibirité

Ibirité, Minas Gerais, Brazil, 30240528

Actively Recruiting

7

City of Igarapé

Igarapé, Minas Gerais, Brazil, 32900-000

Actively Recruiting

8

Centro Universitário FIPMOC

Montes Claros, Minas Gerais, Brazil, 39.408-007

Actively Recruiting

9

City of Nova Lima

Nova Lima, Minas Gerais, Brazil, 34000000

Actively Recruiting

10

Universidade Federal de Ouro Preto

Ouro Preto, Minas Gerais, Brazil, 35400000

Actively Recruiting

11

City of Santa Luzia

Santa Luzia, Minas Gerais, Brazil, 33105160

Actively Recruiting

12

City of Sete Lagoas

Sete Lagoas, Minas Gerais, Brazil, 35700-000

Actively Recruiting

Loading map...

Research Team

G

Gilmar Reis, MD, PhD

CONTACT

E

Eduardo Santos, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms | DecenTrialz